1) histologically confirmed (patients not receiving a single sputum cytology diagnosis) non-small cell lung cancer patients,with wild-type EGFR and ALK-negative; 2) According to IASLC2009 new TNM staging of lung cancer stage <U+2162>B or <U+2163>, previously untreated or relapsed after 1 year of lung cancer resection; 3) have at least one evaluable lesions,according to version 1.1 of the standard in accordance with a judgment RECIST(longest diameter on a spiral CT at least 10mm,on a regular CT longest diameter at least 20mm); 4) Male or female, aged 18 to 75 years; 5) ECOG PS 0 or 1; 6) expected survival at least 3 months; 7) adequate hematological function: absolute neutrophil count (ANC) at least 2×10^9/L and platelet count at least 100×10^9/L and hemoglobin at least 9 g/dL; 8) adequate liver function: total bilirubin less than upper limit of normal (ULN); AST and ALT less than 2.5 times upper limit of normal (ULN); alkaline phosphatase less than 5 times the upper limit of normal (ULN); 9) adequate renal function: serum creatinine less than upper limit of normal (ULN) or calculated creatinine clearance at least 60 mL/min; 10) ECG is normal, there is no non-healing wounds on the body; 11) had not received previous treatment anticancer drugs, or had only received for previous non-metastatic tumors adjuvant or neoadjuvant chemotherapy, but when you start to study treatment has ended more than 6 months; 12) have conducted previous surgery patients required to study treatment was started more than four weeks, and the patient had recovered; 13) have an intact uterus in women prior to enrollment in the study must have a negative pregnancy test result (unless it is already 24 months of amenorrhea) within 28 days. If the pregnancy test from the first administration more than seven days, urine pregnancy test is required for authentication (less than 7 days before the first dose); 14) previous to biological agents, particularly E.coli genetically engineered products without serious allergic reactions; 15) signed informed consent.

NCT02804646_inc_T1
Qualifier
histologically confirmed
NCT02804646_inc_T2
Condition
non-small cell lung cancer
NCT02804646_inc_T3
Qualifier
wild-type EGFR
NCT02804646_inc_T4
Qualifier
ALK-negative
NCT02804646_inc_T5
Measurement
IASLC2009 new TNM staging
NCT02804646_inc_T6
Condition
lung cancer
NCT02804646_inc_T7
Value
stage <U+2162>B or <U+2163>
NCT02804646_inc_T8
Qualifier
untreated
NCT02804646_inc_T9
Qualifier
relapsed
NCT02804646_inc_T10
Temporal
after 1 year of lung cancer resection
NCT02804646_inc_T11
Reference_point
lung cancer resection
NCT02804646_inc_T12
Scope
untreated or relapsed
NCT02804646_inc_T13
Multiplier
at least one
NCT02804646_inc_T14
Condition
evaluable lesions
NCT02804646_inc_T15
Measurement
longest diameter
NCT02804646_inc_T16
Procedure
spiral CT
NCT02804646_inc_T17
Value
at least 10mm
NCT02804646_inc_T18
Procedure
regular CT
NCT02804646_inc_T19
Measurement
longest diameter
NCT02804646_inc_T20
Value
at least 20mm
NCT02804646_inc_T21
Person
Male
NCT02804646_inc_T22
Person
female
NCT02804646_inc_T23
Person
aged
NCT02804646_inc_T24
Value
18 to 75 years
NCT02804646_inc_T25
Measurement
ECOG PS
NCT02804646_inc_T26
Value
0 or 1
NCT02804646_inc_T27
Observation
expected survival
NCT02804646_inc_T28
Temporal
at least 3 months
NCT02804646_inc_T29
Condition
adequate hematological function
NCT02804646_inc_T30
Measurement
absolute neutrophil count (ANC)
NCT02804646_inc_T31
Value
at least 2×10^9/L
NCT02804646_inc_T32
Measurement
platelet count
NCT02804646_inc_T33
Value
at least 100×10^9/L
NCT02804646_inc_T34
Measurement
hemoglobin
NCT02804646_inc_T35
Value
at least 9 g/dL
NCT02804646_inc_T36
Scope
absolute neutrophil count (ANC) at least 2×10^9/L and platelet count at least 100×10^9/L and hemoglobin at least 9 g/dL
NCT02804646_inc_T37
Condition
adequate liver function
NCT02804646_inc_T38
Measurement
total bilirubin
NCT02804646_inc_T39
Value
less than upper limit of normal (ULN)
NCT02804646_inc_T40
Measurement
AST
NCT02804646_inc_T41
Measurement
ALT
NCT02804646_inc_T42
Value
less than 2.5 times upper limit of normal (ULN)
NCT02804646_inc_T43
Measurement
alkaline phosphatase
NCT02804646_inc_T44
Value
less than 5 times the upper limit of normal (ULN)
NCT02804646_inc_T45
Condition
adequate renal function
NCT02804646_inc_T46
Measurement
serum creatinine
NCT02804646_inc_T47
Value
less than upper limit of normal (ULN)
NCT02804646_inc_T48
Measurement
calculated creatinine clearance
NCT02804646_inc_T49
Value
at least 60 mL/min
NCT02804646_inc_T50
Measurement
ECG
NCT02804646_inc_T51
Value
normal
NCT02804646_inc_T52
Negation
no
NCT02804646_inc_T53
Condition
non-healing wounds on the body
NCT02804646_inc_T54
Scope
serum creatinine less than upper limit of normal (ULN) or calculated creatinine clearance at least 60 mL/min
NCT02804646_inc_T55
Scope
total bilirubin less than upper limit of normal (ULN); AST and ALT less than 2.5 times upper limit of normal (ULN); alkaline phosphatase less than 5 times the upper limit of normal (ULN)
NCT02804646_inc_T56
Drug
anticancer drugs
NCT02804646_inc_T57
Negation
not received
NCT02804646_inc_T58
Condition
non-metastatic tumors
NCT02804646_inc_T59
Qualifier
neoadjuvant
NCT02804646_inc_T60
Qualifier
adjuvant
NCT02804646_inc_T61
Procedure
chemotherapy
NCT02804646_inc_T62
Scope
adjuvant or neoadjuvant
NCT02804646_inc_T63
Temporal
ended more than 6 months
NCT02804646_inc_T64
Temporal
previous